Atelvia

Osteoporosis, Malignant Neoplasms, Postmenopause + 3 more
Treatment
5 FDA approvals
20 Active Studies for Atelvia

What is Atelvia

Risedronic acidThe Generic name of this drug
Treatment SummaryRisedronic acid is a medication used to prevent bone loss and the weakening of bones caused by conditions such as osteoporosis and Paget’s disease. It is a type of bisphosphonate, a form of drug that works by blocking the removal of bone cells.
Actonelis the brand name
image of different drug pills on a surface
Atelvia Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Actonel
Risedronic acid
1998
61

Approved as Treatment by the FDA

Risedronic acid, also called Actonel, is approved by the FDA for 5 uses including Therapeutic procedure and Paget’s Disease .
Therapeutic procedure
Paget’s Disease
Bone and Bones
Used to treat increased bone mass in combination with Calcium
Osteoporosis
Used to treat Osteoporosis in combination with Calcium
Postmenopause

Effectiveness

How Atelvia Affects PatientsRisedronate is a medicine that helps prevent bones from being broken down by blocking the activity of cells called osteoclasts.
How Atelvia works in the bodyRisedronatic acid binds to the bones and stops cells that break down bones, called osteoclasts, from doing their job. It does this by entering the cells, becoming acidic, and then inhibiting an enzyme called farnesyl pyrophosphate synthase. This stops the osteoclast from breaking down the bones, which decreases bone resorption.

When to interrupt dosage

The proposed dose of Atelvia is contingent upon the recognized condition, including Therapeutic procedure, Malignant Neoplasms and Postmenopause. The measure fluctuates as per the technique of delivery, as detailed in the table beneath.
Condition
Dosage
Administration
Bone and Bones
30.0 mg, , 5.0 mg, 35.0 mg, 150.0 mg, 75.0 mg, 129.0 mg, 4.9 mg, 30.1 mg, 64.5 mg, 4.3 mg, 25.8 mg
, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Granule, effervescent; Kit; Tablet, Granule, effervescent; Kit; Tablet - Oral, Tablet, delayed release - Oral, Tablet, delayed release, Tablet, Delayed Release - Oral, Kit; Tablet, Kit; Tablet - Oral, Kit, Tablet, Delayed Release
Osteoporosis
30.0 mg, , 5.0 mg, 35.0 mg, 150.0 mg, 75.0 mg, 129.0 mg, 4.9 mg, 30.1 mg, 64.5 mg, 4.3 mg, 25.8 mg
, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Granule, effervescent; Kit; Tablet, Granule, effervescent; Kit; Tablet - Oral, Tablet, delayed release - Oral, Tablet, delayed release, Tablet, Delayed Release - Oral, Kit; Tablet, Kit; Tablet - Oral, Kit, Tablet, Delayed Release
Malignant Neoplasms
30.0 mg, , 5.0 mg, 35.0 mg, 150.0 mg, 75.0 mg, 129.0 mg, 4.9 mg, 30.1 mg, 64.5 mg, 4.3 mg, 25.8 mg
, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Granule, effervescent; Kit; Tablet, Granule, effervescent; Kit; Tablet - Oral, Tablet, delayed release - Oral, Tablet, delayed release, Tablet, Delayed Release - Oral, Kit; Tablet, Kit; Tablet - Oral, Kit, Tablet, Delayed Release
Postmenopause
30.0 mg, , 5.0 mg, 35.0 mg, 150.0 mg, 75.0 mg, 129.0 mg, 4.9 mg, 30.1 mg, 64.5 mg, 4.3 mg, 25.8 mg
, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Granule, effervescent; Kit; Tablet, Granule, effervescent; Kit; Tablet - Oral, Tablet, delayed release - Oral, Tablet, delayed release, Tablet, Delayed Release - Oral, Kit; Tablet, Kit; Tablet - Oral, Kit, Tablet, Delayed Release
Therapeutic procedure
30.0 mg, , 5.0 mg, 35.0 mg, 150.0 mg, 75.0 mg, 129.0 mg, 4.9 mg, 30.1 mg, 64.5 mg, 4.3 mg, 25.8 mg
, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Granule, effervescent; Kit; Tablet, Granule, effervescent; Kit; Tablet - Oral, Tablet, delayed release - Oral, Tablet, delayed release, Tablet, Delayed Release - Oral, Kit; Tablet, Kit; Tablet - Oral, Kit, Tablet, Delayed Release
Paget’s Disease
30.0 mg, , 5.0 mg, 35.0 mg, 150.0 mg, 75.0 mg, 129.0 mg, 4.9 mg, 30.1 mg, 64.5 mg, 4.3 mg, 25.8 mg
, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Granule, effervescent; Kit; Tablet, Granule, effervescent; Kit; Tablet - Oral, Tablet, delayed release - Oral, Tablet, delayed release, Tablet, Delayed Release - Oral, Kit; Tablet, Kit; Tablet - Oral, Kit, Tablet, Delayed Release

Warnings

Atelvia has three contraindications, so it ought not be administered when encountering any of the circumstances outlined in the following table.Atelvia Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Risedronic Acid may interact with Pulse Frequency
Hypocalcemia
Do Not Combine
Postural Orthostatic Tachycardia Syndrome
Do Not Combine
There are 20 known major drug interactions with Atelvia.
Common Atelvia Drug Interactions
Drug Name
Risk Level
Description
Etidronic acid
Minor
The risk or severity of adverse effects can be increased when Risedronic acid is combined with Etidronic acid.
Incadronic acid
Minor
The risk or severity of adverse effects can be increased when Risedronic acid is combined with Incadronic acid.
Tiludronic acid
Minor
The risk or severity of adverse effects can be increased when Risedronic acid is combined with Tiludronic acid.
Acipimox
Moderate
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Risedronic acid is combined with Acipimox.
Aluminium clofibrate
Moderate
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Risedronic acid is combined with Aluminium clofibrate.
Atelvia Toxicity & Overdose RiskTen percent of people taking this drug have reported experiencing back pain, joint pain, stomach pain, and indigestion. Other rare side effects include swelling of the face, skin rashes, eye irritation, and inflammation of the uvea. If someone takes too much of this drug, they may have reduced levels of calcium and phosphorus in their blood. Treatment options include drinking milk or taking antacids to bind the drug and reduce absorption. In more serious cases, a doctor may need to give the patient their stomach contents or intravenous calcium. A single overdose of this drug in rats was found to be 320 to 620 times the

Atelvia Novel Uses: Which Conditions Have a Clinical Trial Featuring Atelvia?

Fifty active trials are being conducted to assess the potential of Atelvia to treat Paget's Disease, Postmenopause and Malignant Neoplasms.
Condition
Clinical Trials
Trial Phases
Postmenopause
5 Actively Recruiting
Phase 2, Not Applicable
Therapeutic procedure
0 Actively Recruiting
Paget’s Disease
0 Actively Recruiting
Bone and Bones
0 Actively Recruiting
Malignant Neoplasms
0 Actively Recruiting
Osteoporosis
27 Actively Recruiting
Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2

Atelvia Reviews: What are patients saying about Atelvia?

5Patient Review
11/10/2014
Atelvia for Decreased Bone Mass Following Menopause
I've been taking Atelvia for over a year and it's shown significant improvements in my condition with no negative side effects that I've experienced. My doctor is happy to keep me on the medication as long as they deem it safe, and I'm very content with the results.
5Patient Review
3/27/2015
Atelvia for Osteoporosis
This medication has been incredibly effective for me. I used to have to give myself a shot every day for two years with no improvement, but this drug has really helped.
4.7Patient Review
10/8/2014
Atelvia for Osteoporosis
I found this much easier to take than Actonel, and I've been taking it for years without any side effects. In most areas, it seems to have kept osteopenia at bay; however, in some areas it has progressed to osteoporosis. Overall, though, it did not improve my condition but prevented it from getting worse in most places.
4Patient Review
9/22/2014
Atelvia for Osteoporosis
I took Forteo to build up my bones and Atelvia to secure the gain (15%). It has been very effective over 3 years. I am 84 years old.
3Patient Review
12/6/2013
Atelvia for Decreased Bone Mass Following Menopause
I was experiencing pain in my joints.
2.3Patient Review
11/18/2014
Atelvia for Osteoporosis
The stomach cramps, diarrhea and joint pain were really unpleasant. I gave it three doses before giving up.
2Patient Review
10/3/2015
Atelvia for Osteoporosis
I took Atelvia for 5 weeks and felt awful for the first three. I developed jaw pain in weeks four and five and had to get x-rays done by a dentist. They told me this medication was bad news and advised me to stop taking it immediately. I'm now on the hunt for more natural methods that don't come with such intense side effects.
2Patient Review
5/15/2015
Atelvia for Osteoporosis
This treatment unfortunately made my stomach upset and gave me indigestion, on top of making me feel generally ill like I had the flu.
1.7Patient Review
10/25/2013
Atelvia for Osteoporosis
I took a sample of this pill less than 24 hours ago and I already feel awful. I've got severe aches and pains, a nasty headache, and nausea. If you're considering this medication, I would not recommend it.
1.7Patient Review
7/8/2014
Atelvia for Osteoporosis
I unfortunately had to stop taking this medication after four weeks due to the severe stomach pain I was experiencing. It's been a real bummer because it seemed to be working well otherwise. If anyone knows of any other treatments for osteoporosis, please let me know.
1.7Patient Review
7/14/2014
Atelvia for Post-Menopausal Osteoporosis Prevention
This medication made me sick in so many ways. Constant diarrhea, headaches, flu symptoms, inflammation, etc. In my opinion, this drug should be taken off the market.
1.7Patient Review
2/22/2014
Atelvia for Osteoporosis
I've only taken one dose of this. It has been 4 days... had a headache the first day . Started getting Very noticeable pain in my femur bone, yesterday and today my ribs are aching. I've been using icepacks on both. I'm afraid to continue this medication... going to call the Dr. on Monday to consult with him.
1.7Patient Review
4/14/2014
Atelvia for Osteoporosis
I had awful intestinal cramps that lasted for weeks, and the diarrhea was incredibly unpleasant. I needed a medication to stop the muscle spasms. Thankfully, I will never have to take this again.
1.3Patient Review
2/25/2014
Atelvia for Decreased Bone Mass Following Menopause
I really dislike the side effects of this drug. They include muscle tightness, leg and arm pain, common cold problems, esophagus problems, jaw bone and thigh bone fractures, among others.
1.3Patient Review
5/6/2014
Atelvia for Decreased Bone Mass Following Menopause
This medicine made me very ill each time I took it. The first day would be fine, but by the second day I would become severely ill with abdominal pain, aches all over my body, diarrhea, low grade fever, and an extreme headache. These symptoms would persist for two to three days before gradually improving; however, even after taking the medication I would still experience abdominal pain whenever I ate anything.
1Patient Review
1/30/2014
Atelvia for Decreased Bone Mass Following Menopause
I was really sick after taking this pill, and it's been a few days and I'm still not feeling great. I would never recommend this medication to anyone.
1Patient Review
5/31/2017
Atelvia for Decreased Bone Mass Following Menopause
The first dose of this medication resulted in weeks of abdominal pain and diarrhea. I was unable to take the second dose as prescribed. This is not an effective treatment for me
1Patient Review
5/6/2014
Atelvia for Osteoporosis
For the last three days, I've been dealing with debilitating muscle pain.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about atelvia

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of Atelvia?

"The individual may experience stomach pain or discomfort, nausea, vomiting, flu-like symptoms, back pain, muscle pain, diarrhea, or constipation."

Answered by AI

How often do you take Atelvia?

"Atelvia may be used to treat osteoporosis in postmenopausal women. It is a delayed-release tablet that is taken once a week."

Answered by AI

What is Atelvia used for?

"Atelvia is a prescription medication used to treat osteoporosis in postmenopausal women. The longevity of Atelvia's efficacy is unknown. You should consult your physician periodically to see if Atelvia is still an appropriate medication for you."

Answered by AI

How long can you take Atelvia?

"Do as your doctor says when taking Atelvia. This includes following directions on the prescription label and reading all medication guides or instruction sheets. Your doctor may sometimes change your dose of the medication. Risedronate is commonly only taken for 3 to 5 years."

Answered by AI

Clinical Trials for Atelvia

Image of Don tyson Center for Agricultural Sciencers in Fayetteville, United States.

Protein and Exercise for Postmenopausal Women

Any Age
Female
Fayetteville, AR
The goal of this clinical trial is to learn if consuming a higher protein diet that includes one serving of beef each day, in combination with resistance exercise, improves wellbeing in postmenopausal women. It will also tell us about how higher protein intake changes body composition and blood values related to health. The main questions it aims to answer are: * Does higher protein intake combined with resistance training improve mood and sleep in postmenopausal women? * What other health benefits to postmenopausal women experience when the follow a higher protein diet and participate in resistance exercise? Researchers will compare three groups 1) postmenopausal women living their daily lives as usual, 2) postmenopausal women consuming a higher protein diet, and 2) postmenopausal women consuming a higher protein diet and participating in resistance training. Participants will: * Consume a higher protein diet for 16 weeks * Participate in an at-home resistance training for 16 weeks * Keep a diary of their food intake, sleep habits, and mood * Have health assessments every 4 weeks
Recruiting
Has No Placebo
Don tyson Center for Agricultural Sciencers (+1 Sites)Jamie Baum
Have you considered Atelvia clinical trials? We made a collection of clinical trials featuring Atelvia, we think they might fit your search criteria.Go to Trials
Image of University of Maryland, Baltimore, Department of Epidemiology and Public Health, Division of Gerontology in Baltimore, United States.

OPTIONS Program for Osteoporosis

65+
All Sexes
Baltimore, MD
Osteoporosis is a disease that weakens bones so the bones may break easily. The risk for osteoporosis increases with age in both women and men. Osteoporosis affects 10 million older adults in the US. Osteoporosis is a common cause of broken bones in the hips and legs. Broken bones can lead to disability, nursing home placement, and death. Because of the dire consequences, a broken hip or leg is one of the most dreaded injuries for older adults. Many studies confirm that a simple regimen of exercise, healthy diet and bone-strengthening medications can improve overall recovery after a broken hip or leg. This regimen can prevent a person from becoming disabled, having future fractures, and even prevent death. Many older adults have surgery in a hospital after breaking a hip or leg. Then older adults go to a skilled nursing facility (SNF) for rehabilitation. Care in SNFs varies greatly. Some patients do not receive the regimen that the investigators know is most beneficial to improve bone health and recovery. Even patients who get exercise, healthy diet, and bone-strengthening medication in the SNF, may not continue with the regimen once patients go home. Therefore, the investigators want to implement and test OsteoPorotic fracTure preventION System (OPTIONS). OPTIONS is a program that will integrate the regimen into the care that is provided in SNFs and after discharge to the community. OPTONS will provide information about exercise, diet, and bone-strengthening medication. OPTIONS will provide doctors, clinical staff, patients, and care partners with the information these stakeholders need to carry out the best-practice regimen. The investigators are partnering with PointClickCare, a large cloud-based healthcare software provider, with SNFs and community care sites across the US. The investigators will include 32 SNFs from different US areas. The investigators will flip a coin to assign SNFs to the intervention (OPTIONS) or the control arm (enhanced usual care) of the study. Enhanced usual care is the care that is typically provided in SNFs after a fracture and adding information about a publicly available fall prevention toolkit. The investigators are using an "implementation science" approach that requires the investigators to get input from the OPTIONS study's vast stakeholder community throughout the study. The OPTIONS study's stakeholders include patients, care partners, clinicians, and professional organizations. The research question is, can using OPTIONS in SNFs and in the community after discharge improve physical function and quality of life in older people in the year after a hip or leg fracture? The investigators are measuring patient-reported outcomes. The investigators will include 1553 patients across the 32 facilities. The investigators have selected outcomes that are important to patients. Specifically, the investigators are measuring patient-reported function and quality of life. The investigators are also measuring patient-reported falls and fractures. The investigators will track the number of patients who die during the study. This study's hypothesis is that patients who receive OPTIONS will report better physical function (i.e., can walk and take better care of themselves) than those who receive enhanced usual care. The investigators also hypothesize that patients that receive OPTIONS will report a better quality of life than those who receive enhanced usual care. This study will provide sound data about the effectiveness of OPTIONS. OPTIONS could then be spread to other SNFs and community-based programs. This would ensure that all older people receive the right care after a hip or leg fracture.
Waitlist Available
Has No Placebo
University of Maryland, Baltimore, Department of Epidemiology and Public Health, Division of Gerontology (+1 Sites)Denise Orwig, PhD
Image of Arthritis Research Canada in Vancouver, Canada.

Virtual Rehabilitation for Spinal Fracture

18+
All Sexes
Vancouver, Canada
Spine fractures are the most common fracture due to osteoporosis. They happen during falls or activities of daily life, like bending to tie shoes. Fractures of the spine can result in pain, which can sometimes last for a long time. Spine fractures can affect breathing, appetite, digestion, and mobility, and can restrict or modify people's work or daily activities. There are no standard rehabilitation programs after spine fracture, and patients often have to pay for rehabilitation. Rehabilitation can be hard to access, especially in rural or remote locations. It can be hard to find health care or rehabilitation providers who specialize in treating spine fractures. After reviewing research and consulting patients and health care providers to understand their experiences with spine fracture rehabilitation, the research team developed a toolkit for a virtual rehabilitation program for people with spine fractures, called VIVA. The research team wants to submit a grant for a clinical trial to implement VIVA in five provinces and determine if VIVA reduces pain and improves physical functioning and quality of life, and if the benefits outweigh the costs. Before this, the team proposes to do a pilot study to test how feasible it is to do a study of VIVA in three provinces.
Waitlist Available
Has No Placebo
Arthritis Research Canada (+5 Sites)Lora Giangregorio, PhD
Have you considered Atelvia clinical trials? We made a collection of clinical trials featuring Atelvia, we think they might fit your search criteria.Go to Trials
Image of Marcus Institute for Aging Research, Hebrew SeniorLife in Boston, United States.

Injury Prevention Care Models for Osteoporosis

65+
All Sexes
Boston, MA
The goal of this clinical trial is to compare three care models for optimizing medications and preventing falls with broken bones in patients receiving rehabilitation after a hospitalization for a broken bone. The primary outcome is injurious falls, with secondary outcomes measuring how the process of care is changed and capturing patient-reported outcomes valued by stakeholders. The main questions this study aims to answer are: * Which of the three models is more effective in preventing falls with fractures? * What are the differences in patient-centered outcomes amongst the three models? These include pain, depression, anxiety, sleep, medication side effect burden, and fear of falling. * What are the differences in osteoporosis treatment and medication burden? The three care models are: a Deprescribing Care Model designed to reduce or stop fall-related medications, a Bone Heath Service Model designed to provide osteoporosis evaluation and management, and an Injury Prevention Service Model offering both services. 42 SNFs will participate in this study. The three models will be incorporated into the routine care of patients at these facilities who are receiving rehabilitation after a hospitalization for a fracture. All care models will be delivered remotely to patients in the SNF and after they transition home by a post-fracture nurse consultant supported by an interprofessional team. This study has three aims. See Detailed Description for more details. This ClinicalTrials.gov record represents the Comparative Effectiveness Aim of the protocol.
Waitlist Available
Has No Placebo
Marcus Institute for Aging Research, Hebrew SeniorLife (+1 Sites)Cathleen S Colon-Emeric, MD, MHS
Image of University of Saskatchewan in Saskatoon, Canada.

Milk + Yogurt for Bone Health

19 - 30
All Sexes
Saskatoon, Canada
Milk and dairy products contain significant amounts of nutrients that contribute to optimal health - nutrients like calcium, vitamin D, and high-quality protein. Fermented milk products or fermented dairy products are dairy foods that have been fermented with certain bacteria. Yogurt is a fermented dairy product containing millions of beneficial bacteria. In this study, the invesgitagtors will look at the effect of milk (a non-fermented dairy product) and yogurt (a fermented dairy product) supplementation on bone health and the amount of fat and muscle mass in Canadian young adults over a 24-month period. While dairy products contain significant amounts of nutrients, the scientific community does not know the impact of long-term supplementation of fermented (i.e., yogurt) or non-fermented (i.e., milk) dairy food on bone health and the amount of fat and muscle mass in young adults. To fill this knowledge gap, the investigators will recruit participants with low calcium intake and assign them to three different groups: 1) milk (intervention) group; 2) yogurt (intervention) group; and 3) control group. The investigators will ask the participants in the milk group to drink 1.5 servings (375 mL) of milk per day for 24 months. Participants in the yogurt group will consume 2 servings (350 g) of yogurt per day for 24 months. Those in the control group will continue their usual diets. Using a randomized controlled trial design, the investigators will measure bone health parameters, hormonal indices related to bone metabolism, body composition (e.g., muscle mass, fat mass), and the number and composition of bacteria living in the gastrointestinal (GI) tract. The hypothesis is that supplementation with yogurt will have more positive effects on bone health indices, particularly femoral neck BMD as the primary outcome, than milk in Canadian adults aged 19-30 years. The secondary hypothesis is that supplementation with yogurt, as a fermented milk product, will have a more beneficial effect than milk on body composition measures. The data will provide valuable information for developing targeted health initiatives and marketing strategies regarding the benefits of fermented and non-fermented dairy product consumption.
Recruiting
Has No Placebo
University of SaskatchewanPhil Chilibeck, PhD
Image of University of Kentucky in Lexington, United States.

Teriparatide vs Alendronate for Osteoporosis

18+
Female
Lexington, KY
Osteoporosis is a health problem of major proportions. It affects more than 40 million Americans and results in more than 2 million fractures annually among Medicare patients alone. Hospital admissions for osteoporotic fractures exceed those of heart attacks, strokes and breast cancer combined. Osteoporosis is commonly considered a disease associated with menopause. This estrogen deficiency related bone loss is characterized by high bone turnover with increased resorption without commensurate changes in bone formation. It is in contrast to age-related bone loss, which starts as early as in the fourth decade of life and continues with increasing age. Age-related bone loss is usually associated with lower bone turnover and decreased bone formation is the main abnormality. Current therapies do not address age-related bone loss and the special needs of the age-related osteoporosis population is currently ignored. This is to a great degree due to difficulties associated with the bone biopsy necessary for unequivocal determination of bone turnover status. Thus, the current standard of care relies on starting with an antiresorber, which is of limited effectiveness in age-related osteoporosis, and in fact impedes the effectiveness of the appropriate anabolic medication. In a current ongoing study - Novel precision medicine approach to treatment of osteoporosis based on bone turnover. EIRB#70781; efforts are focused on addressing this particular problem. Our follow-up study seeks to achieve one specific aim: to compare effectiveness of Alendronate vs Teriparatide after participants have been switched at the end of treatment at year one, to the other drug at year two for the same duration of treatment.
Phase 4
Waitlist Available
University of KentuckyPaul Netzel, DNP
Have you considered Atelvia clinical trials? We made a collection of clinical trials featuring Atelvia, we think they might fit your search criteria.Go to Trials